Table 1.
Clinical data for the study group.
| Feature | Subgroup (estimation based on N = 82 cases) | ||||
|---|---|---|---|---|---|
| MYCN normal (N = 21) | Numerical changes (N = 26) | 2p gain (N = 17) | MNA* (N = 18) | ||
| Patient age | >18 months | 14 (67%) | 12 (46%) | 10 (59%) | 12 (67%) |
| <18 months | 7 (33%) | 14 (54%) | 7 (41%) | 6 (33%) | |
| INSS** 1 | 5 (24%) | 6 (23%) | 3 (18%) | 2 (11%) | |
| INSS 2 | 5 (24%) | 2 (8%) | 0 (0%) | 0 (0%) | |
| Disease stage | INSS 3 | 6 (29%) | 10 (38%) | 3 (18%) | 3 (17%) |
| INSS 4 | 3 (14%) | 6 (23%) | 8 (47%) | 12 (67%) | |
| INSS 4S | 2 (9%) | 2 (8%) | 3 (18%) | 1 (6%) | |
| High | 4 (19%) | 5 (19%) | 7 (41%) | 16 (89%) | |
| Risk group | Intermediate | 6 (29%) | 15 (58%) | 5 (29%) | 2 (11%) |
| Low | 11 (52%) | 6 (23%) | 5 (29%) | 0 (0%) | |
| Metastases | 5 (24%) | 8 (31%) | 11 (65%) | 13 (72%) | |
| Patient outcome | Relapse | 8 (38%) | 7 (27%) | 5 (28%) | 5 (29%) |
| Death | 2 (9.5%) | 2 (8%) | 6 (35%) | 5 (28%) | |
*
MNA, MYCN amplification;
**
INSS, International Neuroblastoma Staging System.